Could an approval of Biogen’s Alzheimer’s therapy still be an option?

For almost any other compound, the nearly unanimous advisory committee vote that Biogen’s Alzheimer’s therapy aducanumab suffered would make its chances of approval vanishingly small. But this mAb has defied gravity before.

FDA’s clear desire to authorize the anti-amyloid agent begs the question of whether a path to market may still exist – and what it would look like...